LONDON: Syncona Ltd’s portfolio company Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases has raised £80 million in an oversubscribed Series B financing. Syncona has committed £19.9 million as part of a leading Series B syndicate, led by Sofinnova, in collaboration with Gilde Healthcare, Forbion, and British Patient…
All posts tagged gene therapy
Syncona launches Beacon Therapeutics with £96 million financing to develop ophthalmic gene therapies
LONDON, UK: London-based healthcare company Syncona Ltd has announced the launch of Beacon Therapeutics Holdings Limited (Beacon Therapeutics), a leading ophthalmic gene therapy company. The company aims to restore and improve the vision of patients with retinal diseases. The launch was made possible through a £96 million ($134 million) Series A financing round. Beacon Therapeutics…